dr. scagliotti discusses egfr mutations in nsclc
Published 13 years ago • 406 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:16
dr. scagliotti on treating egfr-mutated tumors with afatinib
-
1:25
dr. giorgio scagliotti discusses afatinib in patients with egfr mutation
-
0:54
dr. scagliotti on egfr targeted therapy survival benefits
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
15:43
prof. georgio scagliotti, md, phd: lung cancer mutations and the future of treatment
-
1:32
dr. scagliotti discusses elderly lung cancer therapy
-
1:00
dr. scagliotti discusses the future of lung cancer therapy
-
1:49
dr. scagliotti on toxicities related to surgery and chemotherapy in patients with lung cancer
-
6:57
egfr exon 20 mutations in non–small cell lung cancer
-
1:41
egfr mutations in patients with lung cancer
-
2:05
dr. scagliotti on the phase iii ascend-5 study in alk nsclc
-
1:11
dr. gitlitz on egfr exon 20 insertion mutations in lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
1:29
dr. lynch on targeting egfr mutation subtypes in lung cancer
-
1:04
dr. kris discusses egfr mutation testing
-
1:21
detectability of uncommon egfr mutations in nsclc: ngs versus pcr
-
1:10
dr. gubens on prevalence of egfr/alk/ros1 and pd-l1 expression in nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer